Skip to content
About
Technology
Innovators
Students
Industry
Startups
Available Technology

Biomedical, Biotechnology

Nerve-penetrating polymersomes

Inventors: Dr. Jessica Larsen

Market Overview

Nerve injuries occur when a nerve is damaged or compressed, leading to a disruption in its function. Peripheral nerve injuries are located at nerves that connect the brain and spinal cord to the rest of the body and include carpal tunnel syndrome, ulnar nerve compression, and sciatica. There are estimated 50,000 peripheral nerve injuries expected to occur in the US each year. The peripheral nerve injury market in the US was valued at $284.3M in 2021 with expected CAGR of 7.3% through 2030. Traditionally, nerve injuries are treated though surgeries, such as surgical reattachment of nerves or placement of a nerve graft to guide nerve growth, and invasive injections. Therefore, there is a need to development therapies for nerve injuries through less invasive techniques. A Clemson University researcher has developed nanoparticle vesicles that can deliver drugs using non-invasive routes of administrations for the treatment of nerve injuries. These nanoparticles are conjugated with a peptide to increase nerve penetration.

Applications:

Nerve injury treatment, Nanoparticles

Technical Summary:

The proposed nanoparticles are polymersomes that are labeled with the rabies virus glycoprotein peptide (RVG). The addition of RVG induces the association of the polymersomes with proteins expressed on nerve cells, increasing nerve retention. These polymersomes were shown to have nerve-penetration capabilities when delivered intranerve or intramuscular, a less invasive route.

Advantages:

  • Non-invasive – Successful nerve penetration through less invasive administration routes
  • Tunable – Polymersomes can load multiple payloads and have tunable properties
  • Versatile– Could be used in place of surgery or for patients who do not want to undergo surgery for nerve injuries

Download Printable PDF

Technology Overview

State of Development

Proof of Concept

Category

Biomedical, Biotechnology

CURF Reference No.

2024-061

Inventors

Dr. Jessica Larsen


For More Info, Contact:

Pushparajah Thavarajah
Business Development Associate
E: pthavar@clemson.edu
P: (864) 656-0797

Contact

Get Started
Ready to Get Started?

Contact our team at CURF

Contact CURF